Trial Profile
Phase I/II trial of CPT-11 [irinotecan] and temozolomide (Temodar) in patients with recurrent malignant glioma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2018
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; Therapeutic Use
- 09 May 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
- 28 Sep 2005 New trial record.